Clinical Trials Logo

Clinical Trial Summary

Hailey Hailey and Darier disease are rare genetic dermatoses. Mutations of 2 genes (ATP2C1 or ATP2A2 respectively) are responsible for the diseases. These genes have a key role in calcium pump; their defect create abnormal link between keratinocytes' desmosomes and induce skin lesions. Clinically, patients present with inflammatory lesions located in the folds. Quality of life is impaired because of pain, pruritus and tendency to infections. Lesions are permanent but acute exacerbations occur in hot seasons because of increased sweating. Usual therapies are often not effective (local treatment, laser, phototherapy). Because sweating is a well established inducing or aggravating factor, botulism toxin could be an effective treatment for these diseases. Botulism toxin is already used in clinical practice and acts via a decreased sweet secretion. Improvement of skin lesions in Hailey-Hailey or Darier diseases has been previously reported in a few cases but there is no study properly evaluating the benefit of such treatment. The aim of the project is to study the improvement of quality of life for patients suffering from Hailey-Hailey or Darier diseases after a injections of botulism toxin in large skin folds. The principal objective is to estimate the distribution of the variation of quality of life at M1 vs. baseline.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02782702
Study type Interventional
Source University Hospital, Toulouse
Contact
Status Completed
Phase Phase 1
Start date September 2015
Completion date November 2017

See also
  Status Clinical Trial Phase
Completed NCT00074685 - National Registry for Ichthyosis and Related Disorders
Completed NCT05007223 - Skin Microbiome Profile in Hailey-Hailey Disease